Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
AbbVie
(NY:
ABBV
)
201.69
+1.22 (+0.61%)
Streaming Delayed Price
Updated: 2:08 PM EST, Nov 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
62
63
Next >
Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today
November 04, 2024
Via
Benzinga
High-Yield AbbVie Gains Momentum: A 20% Upside Is in Sight
November 04, 2024
High-yielding AbbVie is on track for another 20% gain, which could happen by the end of the year. Analysts are raising their targets, leading to higher prices.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
AbbVie Dividend Increase
November 03, 2024
On 30 October, AbbVie (ABBV) increased its quarterly dividend by 5.81%, from $1.55 to $1.64 per share.
Via
Talk Markets
Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade
November 01, 2024
On Friday, Bristol Myers Squibb stock earned an upgrade to its Relative Strength (RS) Rating, from 62 to 79.
Via
Investor's Business Daily
Price Over Earnings Overview: AbbVie
November 01, 2024
Via
Benzinga
Market Analysis: AbbVie And Competitors In Biotechnology Industry
October 31, 2024
Via
Benzinga
AbbVie's Options Frenzy: What You Need to Know
October 30, 2024
Via
Benzinga
Forecasting The Future: 11 Analyst Projections For AbbVie
October 25, 2024
Via
Benzinga
Check Out What Whales Are Doing With ABBV
October 24, 2024
Via
Benzinga
Market Analysis: AbbVie And Competitors In Biotechnology Industry
October 17, 2024
Via
Benzinga
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
November 01, 2024
The major indexes declined, but haven't fallen apart.
Via
Investor's Business Daily
5 Dividend Stocks to Double Up on Right Now -- Plus Some Dividend ETFs
October 31, 2024
It's hard to beat the power of dividend-paying stocks. They have outperformed non-payers significantly.
Via
The Motley Fool
AbbVie’s Dividend Isn’t As Scary As It Looks
October 30, 2024
AbbVie currently pays shareholders a quarterly dividend of $1.55 per share, which gives the stock a 3.3% yield on the current price.
Via
Talk Markets
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.
Via
Benzinga
Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday?
October 30, 2024
Wall Street experienced a mixed trading session on Wednesday as investors weigh a batch of corporate earnings and fresh economic data.
Via
Benzinga
AbbVie (ABBV) Q3 2024 Earnings Call Transcript
October 30, 2024
ABBV earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
AbbVie Tops Q3 Expectations As Skyrizi, Rinvoq Drive Growth
October 30, 2024
AbbVie's Q3 earnings surpassed expectations with $3.00 EPS and $14.46 billion in revenue. Skyrizi and Rinvoq led growth; AbbVie also raised 2024 EPS guidance.
Via
Benzinga
AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat
October 30, 2024
AbbVie easily beat third-quarter expectations and raised its earnings outlook for the year.
Via
Investor's Business Daily
3 Dividend Growth Stocks to Buy and Never Sell
October 30, 2024
These 3 dividend growth stocks have crushed the market and show no signs of slowing down.
Via
The Motley Fool
Biotech Momentum Trades For The Q4 Rally
October 29, 2024
The biotech sector made an interim peak in late February followed by an active summer in very choppy trading.
Via
Talk Markets
AbbVie Chart Reflects Bearish Signals Ahead Of Q3 Earnings
October 29, 2024
AbbVie (ABBV) reports Q3 earnings Wednesday. The acquisition of Aliada Therapeutics may boost its Alzheimer's portfolio and stock, currently up 33.68% YTD.
Via
Benzinga
Sweetgreen, Tesla, Digital Realty Trust And A Health Care Stock On CNBC's 'Final Trades'
October 28, 2024
Sweetgreen shares closed at $37.48 during Friday's session. Analysts also discuss Tesla, AbbVie and Digital Realty Trust on 'Final Trades'
Via
Benzinga
What Lies In Store For Healthcare ETFs In Q3 Earnings?
October 27, 2024
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited.
Via
Talk Markets
Topics
ETFs
3 Dividend Growth Stocks You Can Buy and Hold Forever
October 26, 2024
These healthcare stocks have fantastic dividend track records.
Via
The Motley Fool
3 High-Yielding Dividend Stocks That Can Be Ideal Buys for Retirees
October 25, 2024
These stocks yield between 2.8% and 3.3% in dividends.
Via
The Motley Fool
Beat the Nasdaq With This Cash-Gushing Dividend Stock
October 23, 2024
The company is performing well despite recently losing its biggest growth driver.
Via
The Motley Fool
3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime
October 23, 2024
These three Vanguard ETFs are worth considering for the long term.
Via
The Motley Fool
Topics
ETFs
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
October 22, 2024
There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle.
Via
Talk Markets
3 Growth Stocks That Could Be Bargain Buys Right Now
October 18, 2024
These stocks trade at less than 20 times their estimated future profits.
Via
The Motley Fool
FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year
October 17, 2024
The FDA approved AbbVie's Vyalev as the first 24-hour subcutaneous infusion therapy for advanced Parkinson's disease, offering improved motor control and reduced symptoms. Approval was based on a...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
...
62
63
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.